This is not the most recent version of the article. View current version (25 JUL 2014)

Intervention Protocol

Mycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantation

  1. Mohamed Kharfan-Dabaja1,2,
  2. Rahul Mhaskar3,
  3. Tea Reljic3,
  4. Joseph Pidala1,
  5. Janelle B Perkins1,
  6. Benjamin Djulbegovic1,4,
  7. Ambuj Kumar3,*

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 12 DEC 2012

DOI: 10.1002/14651858.CD010280


How to Cite

Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantation (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD010280. DOI: 10.1002/14651858.CD010280.

Author Information

  1. 1

    Division of Oncologic Sciences, University of South Florida, Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida, USA

  2. 2

    American University of Beirut, Division of Hematology-Oncology and Bone Marrow Transplantation Program, Beirut, Lebanon

  3. 3

    University of South Florida, Center for Evidence Based Medicine and Health Outcomes Research, Tampa, Florida, USA

  4. 4

    USF Health Clinical Research, University of South Florida, USF Clinical Translational Science Institute, Dpts of Medicine, Hematology and Health Outcome Research, USF and H. Lee Moffitt Cancer Center, Tampa, Florida, USA

*Ambuj Kumar, Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA. akumar1@health.usf.edu. drambujkr@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 12 DEC 2012

SEARCH

This is not the most recent version of the article. View current version (25 JUL 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary objective of this review is to assess the effect of mycophenolate mofetil versus methotrexate for the prevention of acute GVHD in patients undergoing allo-HCT.

Our secondary objectives are to evaluate the effect of methotrexate versus mycophenolate mofetil in terms of the prevention of chronic GVHD, relapse rate, treatment-related harms, and non-relapse mortality.